AzTrials
AzTrials

Rheumatoid ArthritisPhase 2NCT00928512

Efficacy, Safety and Tolerability of AIN457 in Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)

A Phase 2 study testing Secukinmab in people with Rheumatoid Arthritis, run by Novartis Pharmaceuticals at 58 sites in 11 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Rheumatoid Arthritis
What is being tested?
Secukinmab
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
237 participants
Where
58 sitesin 11 countries
Study dates
Jul 2009to Mar 2011
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Presence of RA classified by ACR 1987 revised criteria. Patients with active RA should have been on MTX for at least 3 months and must currently be treated with a stable dose of MTX (> or =7.5 mg/week - < or = 25 mg/week) for at least 4 weeks
  • At Baseline: Disease activity criteria defined by > or = 6 out of 28 tender joints and > or = 6 out of 28 swollen joints WITH either Screening value of hsCRP > or = 10 mg/L OR ESR > or = 28 mm/1st hr

Who cannot join

  • RA patients functional status class IV classified according to the ACR 1991 revised criteria
  • Patients taking high potency opioid analgesics (e.g., methadone, hydromorphone, or morphine)
  • Any therapy by intra-articular injections (e.g. corticosteroid) required for treatment of acute RA flare within 4 weeks before randomization
  • Other protocol-defined inclusion/exclusion criteria may apply

Trial locations and contacts

58 sites in 11 countries.

58 sites in 11 countries

United States13 sites
  • Novartis Investigative Site

    Coeur d'Alene, Idaho, 83814

  • Novartis Investigative Site

    Greenville, South Carolina, 29601

  • Novartis Investigative Site

    Jackson, Tennessee, 38305

  • Novartis Investigative Site

    Kalamazoo, Michigan, 49048

  • Novartis Investigative Site

    Lincoln, Nebraska, 68516

  • Novartis Investigative Site

    Little Rock, Arkansas, 72205

  • Novartis Investigative Site

    Mesa, Arizona, 85202

  • Novartis Investigative Site

    Oklahoma City, Oklahoma, 73103

  • Novartis Investigative Site

    Peoria, Arizona, 85381

  • Novartis Investigative Site

    Rochester, New York, 14609

  • Novartis Investigative Site

    Santa Monica, California, 90404

  • Novartis Investigative Site

    Springfield, Illinois, 62704

  • Novartis Investigative Site

    Tulsa, Oklahoma, 74135-2920

Other trials in United States

Russia9 sites
  • Novartis Investigative Site

    Moscow, 115522

  • Novartis Investigative Site

    Moscow, 117049

  • Novartis Investigative Site

    Moscow, 129327

  • Novartis Investigative Site

    Saint Petersburg, 190068

  • Novartis Investigative Site

    Saint Petersburg, 194104

  • Novartis Investigative Site

    Saint Petersburg, 195257

  • Novartis Investigative Site

    Tula, 300053

  • Novartis Investigative Site

    Tver', 170036

  • Novartis Investigative Site

    Yaroslavl, 150003

Other trials in Russia

Germany6 sites
  • Novartis Investigative Site

    Bayreuth, 95445

  • Novartis Investigative Site

    Berlin, 14059

  • Novartis Investigative Site

    Hamburg, 22081

  • Novartis Investigative Site

    Hamburg, 22415

  • Novartis Investigative Site

    Hildesheim, 31134

  • Novartis Investigative Site

    München, 80639

Other trials in Germany

Japan6 sites
  • Novartis Investigative Site

    Iizuka, Fukuoka, 820-8505

  • Novartis Investigative Site

    Kawagoe, Saitama, 350-1103

  • Novartis Investigative Site

    Kobe, Hyōgo, 650-0044

  • Novartis Investigative Site

    Kobe, Hyōgo, 658-0011

  • Novartis Investigative Site

    Kurashiki, Okayama-ken, 710-8522

  • Novartis Investigative Site

    Sagamihara, Kanagawa, 228-8522

Other trials in Japan

Taiwan6 sites
  • Novartis Investigative Site

    Changhua, 500

  • Novartis Investigative Site

    Kaohsiung City, 81346

  • Novartis Investigative Site

    Niaosong Township, Taiwan, 83301

  • Novartis Investigative Site

    Taichung, Taiwan, 40447

  • Novartis Investigative Site

    Taichung, Taiwan, 40705

  • Novartis Investigative Site

    Taichung, Taiwan ROC, 40201

Other trials in Taiwan

Czechia4 sites
  • Novartis Investigative Site

    Ostrava, Czech Republic, 72200

  • Novartis Investigative Site

    Pardubice, Czech Republic, 53002

  • Novartis Investigative Site

    Prague, 128 50

  • Novartis Investigative Site

    Uherské Hradiště, Czech Republic, 686 01

Other trials in Czechia

South Korea4 sites
  • Novartis Investigative Site

    Anyang-si, Gyeonggi-do, 431-070

  • Novartis Investigative Site

    Busan, Busan, 602-739

  • Novartis Investigative Site

    Seoul, Korea, 137-701

  • Novartis Investigative Site

    Seoul, 143-729

Other trials in South Korea

Hungary3 sites
  • Novartis Investigative Site

    Budapest, 1062

  • Novartis Investigative Site

    Debrecen, 4032

  • Novartis Investigative Site

    Gyula, 5700

Other trials in Hungary

Poland3 sites
  • Novartis Investigative Site

    Bialystok, 15-337

  • Novartis Investigative Site

    Bialystok, 15-461

  • Novartis Investigative Site

    Lublin, 20-607

Other trials in Poland

Slovakia3 sites
  • Novartis Investigative Site

    Banská Bystrica, 975 17

  • Novartis Investigative Site

    Košice, Slovak Republic, 040 15

  • Novartis Investigative Site

    Piešťany, Slovak Republic, 921 12

Other trials in Slovakia

Belgium1 site
  • Novartis Investigative Site

    Brussels, 1200

Other trials in Belgium

About this study

Official title: A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab (AIN457) Followed by an Extension Phase up to a Total of 60 Weeks in Patients With Active Rheumatoid Arthritis Despite Stable Treatment With Methotrexate

This study will assess at Week 16 the efficacy and safety of AIN457 at different doses in patients with active RA despite stable MTX therapy. Treatment will continue up to Week 48 with a safety follow-up at Week 60 to assess the long term efficacy and safety of AIN457 treatment in combination with MTX in RA.

Being tested
Secukinmab, Placebo
Keywords
Rheumatoid Arthritis, RA, ACR, inflammatory joints
Medical subject headings
Arthritis, Rheumatoid

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • SecukinmabDrug

    Also called AIN457

    Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.

  • PlaceboDrug

    Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.

Study groups in NCT00928512
Study groupRoleWhat they receive
Secukinumab 25mgExperimentalSecukinumab 25mg s.c. q4wk
Receives: Drug: Secukinmab
Secukinumab 75mgExperimentalSecukinumab 75mg s.c. q4wk
Receives: Drug: Secukinmab
Secukinumab 150mgExperimentalSecukinumab 150mg s. c. q4wk
Receives: Drug: Secukinmab
Secukinumab 300mgExperimentalSecukinumab 300mg s.c. q4wk
Receives: Drug: Secukinmab
Secukinumab PlaceboPlacebo comparatorSecukinumab Placebo s.c. q4wk
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With American College of Rheumatology Response of 20 (ACR20) at 16 Weeks

    A participant was considered to have achieved the incidence of response (ACR20 criteria) if he/she had at least a 20% improvement in both the tender and swollen 28-joint counts and had at least 20% improvement in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assesseddisability (Health Assessment Questionnaire [HAQ©] score)and acute phase rectant (C-reactive protein [hsCRP]/ESR).

    Measured: 16cweeks

Secondary outcomes (17)
  1. Number of Participants Who Achieved an ACR50 or ACR70 Response at Week 16

    A participant was considered as improved according to the ACR50 or ACR70 criteria if he/she had at least a 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient self-assessed disability (Health Assessment Questionnaire [HAQ©] score) and Acute phase reactant (C-reactive protein [hsCRP]/ESR). Participants were defined as ACR50/70 responders at a given post-randomization visit if they satisfied the ACR50/70 criteria, respectively. Participants were considered ACR50/70 nonresponders if they failed the ACR50/70 criteria respectively. Participants who prematurely discontinued from study due to insufficient therapeutic effect were also considered nonresponders.

    Measured: Week 16

  2. Number of Participants Who Achieved an ACR20, ACR50 or ACR70 Response up to Week 16

    A participant was considered as improved according to the ACR20, ACR50 or ACR70 criteria if he/she had as least a 20%, 50% or 70% improvement, respectively, in both the tender and the swollen 28-joint count, and in at least 3 of the following 5 measures: patient's assessment of rheumatoid athritis (RA) pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's self-assessed disability and acute phase rectant or Erythrocyte sedimentation rate (ESR).

    Measured: at Weeks2, 4, 8, 12, 16

  3. Change From Baseline in Disease Activity Score 28 Using CRP (DAS28-CRP)

    The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient's 'global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission. The DAS28-CRP was derived from swollen joint count, tender joint count, hsCRP and patient's global assessment of disease activity.

    Measured: Baseline, week 16

  4. Change From Baseline in Medical Outcome Short Form (36) Health Survey (SF-36® v2)

    The SF-36 Scale is a 36-item, patient-reported survey which measures overall quality of life. It consists of 8 subscales (vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, mental health) which can be aggregated to derive a physical-component summary score and a mental-component score. Scores are normally determined with the use of norm-based methods which standardize scores based on an assessment of the general U.S. population free of chronic conditions. The scores range for each subscale from 0 to 10, and the composite score ranges from 0 to 100, with the higher scores indicative of better health.

    Measured: Baseline, week 16

  5. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 16

    The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue©) is a 13- item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Participants responded to each item on a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much) based on their experience of fatigue during the past 2 weeThe scale score was computed by summing the item scores, after reversing those items that were worded in the negative direction. When there were missing item scores, the subscale score was computed by summing the non-missing item scores, multiplying by 13 (the total number of items in the scale) and dividing by the number of non-missing items. The latter rule applied only when at least half of the items (seven or more) were non-missing. FACIT-Fatigue subscale scores range from 0 to 52, where higher scores represent less fatigue.

    Measured: Baseline, Week 16

  6. Percentage of Participants With European League Against Rheumatism (EULAR) Response at Week 16

    The distribution of EULAR response criteria was according to DAS28-CRP at Week 16. EULAR response criteria are based on DAS28-CRP status in combination with DAS28-CRP improvements. The EULAR response criteria are as follows: Week 16 DAS28-CRP <3.2 with DAS28-CRP improvement >1.2 corresponds to 'good response'; Week 16 DAS28-CRP <3.2 with DAS28-CRP improvement between 0.6 to 1.2, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement >1.2 or from 0.6 to 1.2, or WeeK 16 DAS28-CRP >5.1 with DAS28-CRP improvement >1.2 correspond to 'moderate response; Week 16 DAS28-CRP <3.2 with DAS28-CRP improvement <0.6, or Week 16 DAS28-CRP between 3.2 to 5.1 with DAS28-CRP improvement <0.6, or Week 16 DAS28-CRP >5.1 with DAS28-CRP improvement between 0.6 to 1.2 or <0.6 correspond to 'no response'.

    Measured: Week 16

  7. Change From Baseline in Rheumatoid Factor (RF) Concentrations at Week 16

    Only values that were above normal range (12 U/mL) were were included.

    Measured: Baseline, Week 16

  8. Anti-CCP (Cyclic Citrulinated Peptide) Antibodies Concentrations at Baseline and at Week 16

    Only values that were above normal range (20 units) were included.

    Measured: Baseline, Week 16

  9. Change From Baseline in ACR Component: Adjusted Swollen 28-joint Count at Week 16

    Synovial fluid and/or soft tissue swelling but not bony overgrowth represents a positive result for swollen joint count. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. Whenever possible, the same evaluator performed these assessments at all visits. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., S) was less than 28, the number of swollen joints (e.g., s) was scaled up proportionately (i.e., 28*(s/S)).

    Measured: Baseline, week 16

  10. Change From Baseline in Disease Activity Score 28 Using ESR (DAS28-ESR) at Week 16

    The DAS28 is a measure of disease activity in Rheumatoid Arthritis (RA). The score is calculated by a complex mathematical formula, which includes the number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR) or hsCRP, and the patient's 'global assessment of global health (indicated by marking a 100 mm line between very good and very bad). A DAS28 score greater than 5.1 implies active disease, less than 3.2 well controlled disease, and less than 2.6 remission.The DAS28 was also derived using erythrocyte sedimentation rate (ESR) (referred to as DAS28-ESR).

    Measured: Baseline, week 16

  11. Change From Baseline in ACR Component: Adjusted Tender 28-joint Count at Week 16

    The ACR tender joint count (28 joints) was done by scoring several different aspects of tenderness as assessed by pressure and joint manipulation on physical examination. Joint counts were performed according to the visit schedule by the physician or by well trained personnel. The following 28 joints were assessed for tenderness and swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). If the number of joints for which data were available (e.g., T) was less than 28, the number of tender joints (e.g., t) was scaled up proportionately (i.e., 28*(t/T)).

    Measured: Baseline, week 16

  12. Change From Baseline in ACR Component: Patient's Assessment of RA Pain at Week 16

    The patient's assessment of pain was performed at all visits using 100 mm visual analog scale (VAS) ranging from "no pain" to "unbearable pain" after the question "Please indicate with a vertical mark ( | ) through the horizontal line the most pain you had from your rheumatoid arthritis over the last 24 hours.

    Measured: Baseline, week 16

  13. Change From Baseline in ACR Component: Patient's Global Assessment of Disease Activity at Week 16

    The patient's global assessment of disease activity was performed at the visits on a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, "Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing".

    Measured: Baseline, week 16

  14. Change From Baseline in ACR Component: Physician's Global Assessment of Disease Activity at Week 16

    The physician's global assessment of disease activity was performed at the visits usingon a 100 mm non-anchored visual analog scale, from no arthritis (0) activity to maximal arthritis (100) activity, after the question, "Considering all the ways your arthritis affects you, draw a line on the scale for how well you are doing".

    Measured: Baseline, week 16

  15. Change From Baseline in ACR Component: Health Assessment Questionnaire (HAQ©) Score at Week 16

    HAQ© was used to assess physical ability and functional status of patients as well as quality of life at the visits in these 8 categories assessed by the Disability Index: dressing \& grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. Patients report amount of difficulty they have in performing 2 or 3 specific activities. There are 4 possible responses (0, 1, 2, 3) for these questions which include types of assistance, if any; the participant uses for his/her usual activities: 0: without any difficulty- No assistance is needed; 1: with some difficulty - A special device is used by the patient in his/her usual activities; 2: with much difficulty - The patient usually needs help from another person. 3: Unable to do - the patient usually needs both a special device and help from another person. Scores of 0 - 1 are generally considered to represent mild to moderate difficulty, 1-2 moderate to severe disability, and 2 -3 severe to very severe disability.

    Measured: Baseline, week 16

  16. Change From Baseline in ACR Component: High Sensitivity C-reactive Protein (hsCRP)

    Blood for this assessment was obtained at the visits in order to identify the presence of inflammation, to determine its severity, and to monitor response to treatment.Since the results of this test may have unblinded study personnel, results from the central lab were provided for screening and baseline only. The hsCRP results from samples collected during the treatment period were revealed only after final database lock.

    Measured: Baseline, week 16

  17. Change From Baseline in ACR Component: Erythrocyte Sedimentation Rate (ESR) at Week 16

    Blood for ESR, which is helpful to diagnose inflammatory diseases and to monitor disease activity and response to therapy, was obtained at the visits.

    Measured: Baseline, week 16

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jun 2009 (estimated)
  2. Study startJul 2009
  3. Primary completionMar 2011
  4. Study completionMar 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
237 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00928512
Sponsor's protocol ID
CAIN457F2201
Other IDs
2009-011000-34, 2009
Status last verified
Oct 2015
First submitted
25 Jun 2009
Last updated
30 Oct 2015
Data monitoring committee
No

Publications

  • Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014 Mar;41(3):414-21. doi: 10.3899/jrheum.130637. Epub 2014 Jan 15.

    PubMed 24429175
  • Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Mpofu S. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013 Jun;72(6):863-9. doi: 10.1136/annrheumdis-2012-201601. Epub 2012 Jun 23.

    PubMed 22730366

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Secukinmab in people with Rheumatoid Arthritis, run by Novartis Pharmaceuticals at 58 sites in 11 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 58 sites in United States, Russia, Germany, Japan, Taiwan and 6 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Jul 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With American College of Rheumatology Response of 20 (ACR20) at 16 Weeks (time frame: 16cweeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00928512, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in